Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
News & Press: Industry News

Amgen loss 'a temporary blip' for Seattle biotech: Man behind Arch Venture's $400M fund speaks out

Wednesday, August 27, 2014   (0 Comments)
Posted by: Megan Jeffrey
Share |
Amgen loss 'a temporary blip' for Seattle biotech: Man behind Arch Venture's $400M fund speaks out | Puget Sound Business Journal 

more WBBA Calendar

4/21/2015
Life Science Nation Fundraising Boot Camp for Emerging Companies

4/21/2015
WBBA VIP Forum with Madigan Army Medical Center

Featured Partners
BioTech Primer Inc.BioTech Primer develops and delivers customized training to the Life Sciences community

Membership Management Software Powered by YourMembership.com®  ::  Legal